Literature DB >> 11281191

Gut mucosal secretion of interleukin 1beta and interleukin-8 predicts relapse in clinically inactive Crohn's disease.

I D Arnott1, H E Drummond, S Ghosh.   

Abstract

Trials of maintenance therapy in Crohn's disease are often underpowered, and there is need for objective markers of relapse. We assessed the relationship of whole gut lavage fluid cytokines to relapse in inactive Crohn's disease. Fifty-four patients with inactive Crohn's disease were prospectively assessed. Inactivity was determined as a Crohn's disease activity index of <150 and whole gut lavage fluid immunoglobulin G <10 microg/ml. All patients underwent whole gut lavage with analysis of IL-1beta and IL-8. Follow up was for one year. Patients with elevated whole gut lavage fluid IL-1beta (P < 0.004) and IL-8 (P < 0.02) had greater chance of relapse. Young age, short disease duration, and fistulating disease also relapsed more frequently. Multiple regression identified IL-1beta as an independent variable. In conclusion, an elevated whole gut lavage fluid IL-1beta in inactive Crohn's disease identifies patients at high risk of relapse.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11281191     DOI: 10.1023/a:1005617302718

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  35 in total

Review 1.  Pro-inflammatory cytokines in inflammatory bowel disease.

Authors:  M E McAlindon; Y R Mahida
Journal:  Aliment Pharmacol Ther       Date:  1996       Impact factor: 8.171

2.  Classification of inflammatory bowel disease.

Authors:  J E Lennard-Jones
Journal:  Scand J Gastroenterol Suppl       Date:  1989

3.  Gut lavage fluid protein concentrations: objective measures of disease activity in inflammatory bowel disease.

Authors:  C P Choudari; S O'Mahony; G Brydon; O Mwantembe; A Ferguson
Journal:  Gastroenterology       Date:  1993-04       Impact factor: 22.682

4.  Crohn's disease: concordance for site and clinical type in affected family members--potential hereditary influences.

Authors:  T M Bayless; A Z Tokayer; J M Polito; S A Quaskey; E D Mellits; M L Harris
Journal:  Gastroenterology       Date:  1996-09       Impact factor: 22.682

5.  Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables.

Authors:  C Cammà; M Giunta; M Rosselli; M Cottone
Journal:  Gastroenterology       Date:  1997-11       Impact factor: 22.682

6.  Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease.

Authors:  R Daig; T Andus; E Aschenbrenner; W Falk; J Schölmerich; V Gross
Journal:  Gut       Date:  1996-02       Impact factor: 23.059

7.  Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis.

Authors:  R G Farmer; G Whelan; V W Fazio
Journal:  Gastroenterology       Date:  1985-06       Impact factor: 22.682

8.  Identifying patients with a high risk of relapse in quiescent Crohn's disease. The GETAID Group. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.

Authors:  T Sahmoud; G Hoctin-Boes; R Modigliani; A Bitoun; J F Colombel; J C Soule; C Florent; J P Gendre; E Lerebours; R Sylvester
Journal:  Gut       Date:  1995-12       Impact factor: 23.059

9.  Interleukin 8: cells of origin in inflammatory bowel disease.

Authors:  M C Grimm; S K Elsbury; P Pavli; W F Doe
Journal:  Gut       Date:  1996-01       Impact factor: 23.059

10.  C-reactive protein as a predictor of relapse in asymptomatic patients with Crohn's disease.

Authors:  C André; L Descos; J Vignal; J Gillon
Journal:  Scott Med J       Date:  1983-01       Impact factor: 0.729

View more
  6 in total

1.  Pit patterns in rectal mucosa assessed by magnifying colonoscope are predictive of relapse in patients with quiescent ulcerative colitis.

Authors:  Y Nishio; T Ando; O Maeda; K Ishiguro; O Watanabe; N Ohmiya; Y Niwa; K Kusugami; H Goto
Journal:  Gut       Date:  2006-05-08       Impact factor: 23.059

2.  Genetically modified enterotoxigenic Escherichia coli vaccines induce mucosal immune responses without inflammation.

Authors:  Alexandra Daley; Roger Randall; Michael Darsley; Naheed Choudhry; Nicola Thomas; Ian R Sanderson; Nick M Croft; Paul Kelly
Journal:  Gut       Date:  2007-06-12       Impact factor: 23.059

3.  Hemorrhagic shock induces a proinflammatory milieu in the gut lumen.

Authors:  Dennis I Sonnier; Amy T Makley; Lou Ann W Friend; Stephanie R Bailey; Alex B Lentsch; Timothy A Pritts
Journal:  J Surg Res       Date:  2011-03-31       Impact factor: 2.192

4.  Vectorial secretion of interleukin-8 mediates autocrine signalling in intestinal epithelial cells via apically located CXCR1.

Authors:  Oriana Rossi; Jurgen Karczewski; Ellen H Stolte; Robert J M Brummer; Michiel A van Nieuwenhoven; Marjolein Meijerink; Joost R J van Neerven; Sven C D van Ijzendoorn; Peter van Baarlen; Jerry M Wells
Journal:  BMC Res Notes       Date:  2013-10-28

Review 5.  Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification.

Authors:  Bjoern Titz; Raffaella M Gadaleta; Giuseppe Lo Sasso; Ashraf Elamin; Kim Ekroos; Nikolai V Ivanov; Manuel C Peitsch; Julia Hoeng
Journal:  Int J Mol Sci       Date:  2018-09-15       Impact factor: 5.923

6.  Morning Cortisol and Circulating Inflammatory Cytokine Levels: A Mendelian Randomisation Study.

Authors:  Skanda Rajasundaram; Rezbieara P Rahman; Benjamin Woolf; Sizheng Steven Zhao; Dipender Gill
Journal:  Genes (Basel)       Date:  2022-01-08       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.